

# How knowledge-sharing can change the standards of fertility care

CREATING THE BEST JOURNEY FOR EVERY CLINIC AND EVERY PATIENT



In the world of fertility, the rapid development of assisted reproductive technologies (ART) has led to pivotal advances in IVF laboratories, improving fertility outcomes and patient safety. It is anticipated that the next leap forward will involve the harnessing of technologies to drive standardization, automation and digitalization of clinics.

As a global leader in delivering innovative solutions in the field of assisted reproductive technology and genomics, CooperSurgical aims to support clinics in embracing and successfully implementing this change process as an essential element of the progression to the fertility care of the future. Through the intelligent and targeted collection of data and utilization of key performance indicators (KPIs) and data metrics, clinics can work towards the standardization of laboratory procedures and provision of individualized treatments based on specific patient needs. As well as helping patients in making better informed decisions, clinics can share their knowledge to drive improvements in fertility care worldwide.

## THE POWER OF DATA

Collection of data is not an end in itself, but, in the words of Carla Fiorina (ex-CEO of Hewlett Packard), "the goal is to turn data into information and information into insight." Useful information on the patient journey and on clinic performance is being generated continuously by IVF clinics, but data might be missed or, worse still, collected but not used to drive optimization. Through digitalization, clinics have the opportunity to make the most of this data to produce the metrics needed to improve, optimize and standardize procedures and protocols.

"When we offer support to a clinic, their data not only gives us a clearer understanding of their processes and performance, but also highlights the vital data that might be missing, data that could give insights into how to strengthen the clinical practices," says Inge Errebo, Senior Director of Professional Education and Clinical Support at CooperSurgical. "Data is crucial – if you don't have the data, you don't have any KPIs."

Automation of processes and, importantly, data management is a prerequisite to the collection of complete data sets that then generate metrics or KPIs that facilitate quality improvements. In short, data is turned into insights that might then be shared to the benefit of clinics and patients globally.

## DATA COLLECTION DRIVES QUALITY IMPROVEMENTS

For IVF laboratories, data can support standardization, ensuring that all procedures are performed consistently, thereby promoting optimized laboratory performance and positively impacting patient outcomes. Automated data collection makes this process much more manageable, especially in busy centers.

"One of the key benefits of standardization is that it increases consistency of performance and predictability of laboratory outcomes," says Rob Thompson, Director of Digital Innovation at CooperSurgical. "For embryologists carrying out the procedures, this standardization, coupled with adoption of best practices, can give IVF clinics the confidence they are performing optimally and producing the best possible treatment outcomes for their patients."



CooperSurgical developed the RI Witness™ ART Management System, which integrates automated data collection, as a companion to the work done by the embryologists. This type of automation and tracking provides insights to help ensure chain of custody, traceability, efficient workflow management and quality control. RI Witness™ also helps to assess adherence to standard operating procedures and supports standardization.

Automation and data management will have a potentially profound impact on the way laboratories work. "The role of the embryologist is also changing as we move towards more technology and data analysis," says Dr. Marcos Meseguer, Scientific Supervisor and Senior Embryologist at the IVI Valencia, Spain. "I don't think the job of an embryologist is in jeopardy, but the role will continue to shift to include more research and data management."

## THE RIGHT KNOWLEDGE GOES A LONG WAY

Though data utilization will help the drive towards standardization and optimization, this is further enhanced when combined with knowledge sharing and high-quality training in technical skills. Through observation and troubleshooting in many different labs, as well as bringing together a wealth of expertise, CooperSurgical seeks to actively support, train and educate professionals in all disciplines to promote the highest standards and best practices.

"We can use education, training and knowledge-sharing to help increase the standards of fertility treatment in the clinic," says Rachel Chin, Clinical Applications Manager at CooperSurgical, "to help strengthen the core practices in each clinic and provide them with a solid foundation for ongoing quality improvement."

## THE FUTURE OF FERTILITY CARE IS ALREADY HERE

The fertility industry is changing with advances such as CooperSurgical's RI Witness™ lab management system and the PGTaiSM 2.0 technology platform. For example, PGTaiSM 2.0 harnesses the power of artificial intelligence (AI) and machine learning to improve the interpretation of PGT-A results. Both are examples of the role emerging technologies will continue to play.

Delivering standardization, automation and digitalization to clinics, along with training and knowledge-sharing, are not just for the benefit of one clinic but are part of a larger commitment for the fertility industry to work more closely and more collaboratively. Knowledge shared among lab practitioners, clinicians, nurses and clinic managers has the potential to improve the quality of fertility care for IVF clinics around the world.

Learn how RI Witness™ can help increase overall laboratory efficiency: [fertility.coopersurgical.com/equipment/ri-witness/](https://fertility.coopersurgical.com/equipment/ri-witness/)



# BJOG

An International Journal of  
Obstetrics and Gynaecology



Royal College of  
Obstetricians &  
Gynaecologists

# Care of Women Presenting with Suspected Preterm Prelabour Rupture of Membranes from 24<sup>+0</sup> Weeks of Gestation

Green-top Guideline No. 73

June 2019

*Please cite this paper as:* Thomson AJ, on behalf of the Royal College of Obstetricians and Gynaecologists. Care of Women Presenting with Suspected Preterm Prelabour Rupture of Membranes from 24<sup>+0</sup> Weeks of Gestation. BJOG 2019;126:e152–166

Tweetable abstract: #GreenTopGuideline No. 73 recommends how to diagnose & care for suspected #PPROM from 24 + 0 to 36 + 6 weeks of gestation.



## Care of Women Presenting with Suspected Preterm Prelabour Rupture of Membranes from 24<sup>+0</sup> Weeks of Gestation

AJ Thomson, on behalf of the Royal College of Obstetricians and Gynaecologists

*Correspondence:* Royal College of Obstetricians and Gynaecologists, 27 Sussex Place, Regent's Park, London NW1 4RG.  
Email: [clinicaleffectiveness@rcog.org.uk](mailto:clinicaleffectiveness@rcog.org.uk)

### 1. Key recommendations

- The diagnosis of spontaneous rupture of the membranes is made by maternal history followed by a sterile speculum examination. [Grade D]
- If, on speculum examination, no amniotic fluid is observed, clinicians should consider performing an insulin-like growth factor-binding protein I (IGFBP-I) or placental alpha microglobulin-I (PAMG-I) test of vaginal fluid to guide further management. [Grade B]
- Following the diagnosis of preterm prelabour rupture of the membranes, (PPROM) an antibiotic (preferably erythromycin) should be given for 10 days or until the woman is in established labour (whichever is sooner). [Grade A]
- Women who have PPRM between 24<sup>+0</sup> and 33<sup>+6</sup> weeks' gestation should be offered corticosteroids; steroids can be considered up to 35<sup>+6</sup> weeks' gestation. [Grade A]
- A combination of clinical assessment, maternal blood tests (C-reactive protein and white cell count) and fetal heart rate should be used to diagnose chorioamnionitis in women with PPRM; these parameters should not be used in isolation. [Grade D]
- Women whose pregnancy is complicated by PPRM after 24<sup>+0</sup> weeks' gestation and who have no contraindications to continuing the pregnancy should be offered expectant management until 37<sup>+0</sup> weeks; timing of birth should be discussed with each woman on an individual basis with careful consideration of patient preference and ongoing clinical assessment. [Grade A]
- In women who have PPRM and are in established labour or having a planned preterm birth within 24 hours, intravenous magnesium sulfate should be offered between 24<sup>+0</sup> and 29<sup>+6</sup> weeks of gestation. [Grade A]

### 2. Background and scope

Preterm prelabour rupture of membranes (PPROM) complicates up to 3% of pregnancies and is associated with 30–40% of preterm births.<sup>1</sup> PPRM can result in significant neonatal morbidity and mortality, primarily from prematurity, sepsis, cord prolapse and pulmonary hypoplasia. In addition, there are risks associated with chorioamnionitis and placental abruption.<sup>2</sup>

The median latency after PPRM is 7 days and tends to shorten as the gestational age at PPRM advances.<sup>3,4</sup>

This guideline comprises recommendations relating to the diagnosis, assessment, care and timing of birth of women presenting with suspected PPRM from 24<sup>+0</sup> to 36<sup>+6</sup> weeks of gestation. It also addresses care in a subsequent pregnancy. An infographic and audio version to supplement this guideline are available online (Infographic SI,

Audio S1). It supplements NICE guideline (NG25), *Preterm labour and birth* (published November 2015).<sup>5</sup> Relevant recommendations can also be found in the Royal College of Obstetricians and Gynaecologists (RCOG) Green-top Guideline [GTG no. 36], *Early-onset of Group B Streptococcal Disease*.<sup>6</sup>

### 3. Identification and assessment of evidence

The Cochrane Library and electronic databases (DARE, EMBASE, Trip, MEDLINE and PubMed) were searched looking for the following terms in the title or abstract ‘preterm prelabour rupture of membranes’, ‘amnioinfusion’, ‘chorioamnionitis,’ ‘intra-amniotic infection’, ‘IGFBP-1’, ‘PAMG-1’, ‘amniocentesis’, ‘antenatal corticosteroids’ and ‘tocolytics’. The search was restricted to articles published until January 2019. The full search strategy is available to view online as supporting information (Appendix S1 and S2).

This guideline was developed using the methodology described in Clinical Governance Advice 1 (a-c).<sup>7</sup>

### 4. Diagnosis

#### 4.1 How is the diagnosis of PPRM made?

Recommendation	Evidence Level	Strength	Rationale for the recommendation
<b>The diagnosis of spontaneous rupture of the membranes is made by maternal history followed by a sterile speculum examination demonstrating liquor</b>	4	D	Given that this is the ‘gold standard’, further trials are unlikely to add to the evidence for this recommendation
<b>If, on speculum examination, no amniotic fluid is observed, clinicians should consider performing an IGFBP-1 or PAMG-1 test of vaginal fluid to guide further management</b>	2++	B	Recommended in NG25. <sup>5</sup> Studies have reported high levels of sensitivity and specificity for these markers
<b>The role of ultrasound assessment of amniotic fluid volume is unclear</b>	4	✓	No specific studies identified in the role of liquor volume in supporting the diagnosis of PPRM

The presence of a pool of fluid in the vagina at sterile speculum examination is highly suggestive of membrane rupture, and when this is clearly observed no further diagnostic tests are required.<sup>5</sup> Some clinicians recommend that the woman lies flat or in the left lateral for a period of time before speculum examination to allow the amniotic fluid to accumulate, though no evidence was identified to support these practices. Based on clinical evaluation, the diagnosis of PPRM can be equivocal in 10–20% of cases. When a pool of amniotic fluid is not clearly observed, consideration should be given to testing for IGFBP-1 or PAMG-1 if these tests are available, and further management undertaken as per NG25.<sup>5</sup> Several studies investigating these biochemical markers have found high levels of sensitivity and specificity.<sup>8,9</sup> NG 25 emphasises that the test results for IGFBP-1 or PAMG-1 should not be used alone to decide what care to offer the woman and that clinical condition, medical and pregnancy history, and gestational age

Evidence level 4

should be taken in to account. Testing for nitrazine is not recommended, and no further tests are required if the woman is in established labour.<sup>5</sup>

No studies were identified specifically addressing ultrasound to determine amniotic fluid volumes in women presenting with suspected PPRM. Ultrasound examination demonstrating oligohydramnios may be useful to support the clinical diagnosis of PPRM.

If PPRM is not confirmed, the woman can return to her previous schedule of antenatal care; NG25 recommends that women should be advised to return if they have any further symptoms suggestive of PPRM or preterm labour.<sup>5</sup>

Evidence level 4

It is routine practice in the UK to obtain a vaginal swab for microbiological testing while diagnosing PPRM, although evidence to support this practice is lacking. Group B streptococcus colonization may be identified, which would influence the timing of birth (section 7.1). A prospective cohort study assessed the vaginal microbiome in women following PPRM; this concluded that following PPRM the vaginal microbiome was abnormal but the profile did not correlate with latency duration.<sup>10</sup>

Evidence level 2+

## 5. Assessment

### 5.1 What is required antenatally to identify infection?

Recommendation	Evidence Level	Strength	Rationale for the recommendation
<b>A combination of clinical assessment, maternal blood tests (C-reactive protein and white cell count) and fetal heart rate should be used to diagnose chorioamnionitis in women with PPRM; these parameters should not be used in isolation</b>	4	D	Recommended by NG25 <sup>5</sup>
<b>Women should be advised of, and observed for, symptoms of clinical chorioamnionitis (lower abdominal pain, abnormal vaginal discharge, fever, malaise and reduced fetal movements)</b>	4	D	Recommended by NG25 <sup>5</sup>

One of the risks associated with PPRM is ascending infection leading to chorioamnionitis, and subsequent fetal and neonatal infection. NG25<sup>5</sup> recommends that a combination of clinical assessment (pulse, blood pressure, temperature and symptoms), maternal blood tests (C-reactive protein and white cell count) and fetal heart rate using cardiotocography, should be employed to diagnose clinical infection. If the results of the clinical assessment or any of the tests are not consistent with each other, it is recommended that the woman should continue to be observed and consideration should be given to repeating the tests as per NG25.<sup>5</sup>

Evidence level 4

The white cell count will rise 24 hours following administration of corticosteroids and should return to baseline 3 days following administration.<sup>11</sup> While a study investigating several maternal serum markers for predicting histological chorioamnionitis after PPRM concluded that a raised C-reactive protein was most informative,<sup>12</sup> a systematic review and meta-analysis of 13 observational studies found that

Evidence level 2++

C-reactive protein has a sensitivity of only 68.7% and specificity of 77.1% in diagnosing histological chorioamnionitis.<sup>13</sup>

When cared for as an inpatient, women with PPRM should have their vital signs, including pulse, blood pressure, respiratory rate and temperature, recorded on an obstetric early warning chart.<sup>14</sup> They should also be observed for clinical symptoms and signs of infection. When cared for as an outpatient, women should be advised of the symptoms of chorioamnionitis and be reviewed regularly (including blood tests [white cell count and C-reactive protein], clinical recordings and fetal heart rate monitoring), for example, in a day care unit, maternity triage or antenatal ward, one or two times each week; if the woman has any concerns, she should attend the hospital immediately.

## 5.2 *Should neonatologists be involved in the woman's care?*

Recommendation	Evidence Level	Strength	Rationale for the recommendation
<b>Neonatologists should be informed when the diagnosis of PPRM is confirmed and delivery is anticipated</b>	4	✓	It is important to ensure that the neonatal unit has the appropriate staff and facilities to care for the neonate should delivery occur
<b>Women with PPRM should have the opportunity to meet with a neonatologist antenatally to discuss their baby's care</b>	4	✓	This would be regarded as good practice

PPROM is associated with increased perinatal morbidity and mortality, and often leads to preterm birth.<sup>1</sup> Neonatologists should be informed once the diagnosis of PPRM has been made and delivery is anticipated to ensure that the neonatal unit has the appropriate staff and facilities to care for the neonate should delivery occur.

Where possible, once the diagnosis has been confirmed, women with PPRM and their partners should be offered the opportunity to meet with a neonatologist to discuss their baby's care.

## 6. Management

### 6.1 *Should antibiotics be given?*

Recommendation	Evidence Level	Strength	Rationale for the recommendation
<b>Erythromycin should be given for 10 days following the diagnosis of PPRM, or until the woman is in established labour (whichever is sooner)</b>	1++	A	A Cochrane review found benefits when antibiotics were administered: reduced chorioamnionitis, prolonged latency and improved neonatal outcomes Recommended by NG 25 <sup>5</sup>

A Cochrane review investigating the role of antibiotics for women with confirmed PPROM found that the use of antibiotics is associated with a statistically significant reduction in chorioamnionitis (RR 0.66, 95% CI 0.46–0.96). There was a significant reduction in the numbers of babies born within 48 hours (RR 0.71, 95% CI 0.58–0.87) and 7 days (RR 0.79, 95% CI 0.71–0.89). Neonatal infection, use of surfactant, oxygen therapy and abnormal cerebral ultrasound prior to discharge from hospital was also reduced. There was no significant reduction in perinatal mortality<sup>15</sup> or on the health of the children at 7 years of age.<sup>16</sup> The antibiotic of choice and optimal duration of treatment are not clear; erythromycin 250 mg four times a day for 10 days or until the woman is in established labour (whichever is sooner), is recommended in NG25.<sup>5</sup> Penicillin may be used in women who cannot tolerate erythromycin. Alternative antibiotic regimens have been investigated.<sup>17,18</sup> Co-amoxiclav should be avoided as it is associated with an increased risk of neonatal necrotising enterocolitis,<sup>19</sup> and antibiotics should not be given unless the diagnosis of PPROM is confirmed.

Evidence level I++

## 6.2 What is the role of antenatal corticosteroids?

Recommendation	Evidence Level	Strength	Rationale for the recommendation
<b>In women who have PPROM from 24<sup>+0</sup> weeks, antenatal corticosteroids should be:</b>			Corticosteroids recommended by NG25 <sup>5</sup> and supported by a meta-analysis of randomised controlled trials
● offered between 24 <sup>+0</sup> and 25 <sup>+6</sup> weeks of gestation	<b>2++</b>	<b>B</b>	Large cohort studies demonstrate benefits of steroids for babies born between 24 <sup>+0</sup> and 25 <sup>+6</sup> weeks of gestation
● offered between 26 <sup>+0</sup> and 33 <sup>+6</sup> weeks of gestation	<b>1++</b>	<b>A</b>	High-quality evidence that steroids reduce the incidence of intraventricular haemorrhage and the need for mechanical ventilation in PPROM
● considered between 34 <sup>+0</sup> and 35 <sup>+6</sup> weeks of gestation	<b>1++</b>	<b>A</b>	Given the high 'number to treat' and the potential side effects of steroids, administration should be evaluated on an individual basis

A meta-analysis of 17 randomised controlled trials has demonstrated that the administration of corticosteroids to women with PPROM reduces the risks of respiratory distress syndrome (RR 0.81, 95% CI 0.67–0.98) and intraventricular haemorrhage (RR 0.49, 95% CI 0.25–0.96). No difference was observed between steroid and control groups concerning the risk for necrotising enterocolitis, neonatal sepsis and Apgar score of less than 7 at 5 minutes. Perinatal mortality was similar between steroid and control groups.<sup>20</sup> A meta-analysis of observational studies suggest no increased risk of chorioamnionitis or neonatal sepsis with maternal steroid use.<sup>21</sup>

Evidence level I++

NG25<sup>5</sup> addresses the administration of corticosteroids to women with PPROM from 24<sup>+0</sup> until 35<sup>+6</sup> weeks of gestation, recommending that when offering or considering corticosteroids a discussion should take place with the woman about how steroids may help and the potential risks associated with their administration. Furthermore, NG25 recommends that repeat courses of corticosteroids should not be routinely offered but that the interval since the last course, the gestational age and the likelihood of birth in the next 48 hours, should be taken in to account.<sup>5</sup>

Evidence level 4

This Green-top Guideline covers the care of women presenting with suspected PPROM from 24<sup>+0</sup> weeks' gestation. NG25<sup>5</sup> recommends that corticosteroids should be *considered* between 24<sup>+0</sup> and 25<sup>+6</sup> weeks' gestation. There is now good evidence that corticosteroid administration has benefits when given to women who give birth at less than 25<sup>+6</sup> weeks' and indeed, at less than 24<sup>+0</sup> weeks'.<sup>22,23</sup> In contrast to NG25<sup>5</sup> we therefore recommend that corticosteroids should be *offered* from at least 24<sup>+0</sup> weeks' gestation.

Evidence level 2+

### 6.3 What is the role of magnesium sulfate for neuroprotection of the baby?

Recommendation	Evidence Level	Strength	Rationale for the recommendation
<b>In women who have PPROM and are in established labour or having a planned preterm birth within 24 hours, intravenous magnesium sulfate should be offered between 24<sup>+0</sup> and 29<sup>+6</sup> weeks of gestation</b>	<b>1++</b>	<b>A</b>	Recommended by NG25 <sup>5</sup> and supported by meta-analyses of randomised controlled trials that have shown a reduction in cerebral palsy

Meta-analyses of randomised controlled trials have demonstrated that the administration of magnesium sulfate to women in established preterm labour or having a planned preterm birth in the following 24 hours, reduces cerebral palsy (RR 0.69, 95% CI 0.55–0.88) and motor dysfunction in the offspring (RR 0.6, 95% CI 0.43–0.83).<sup>24–26</sup> The benefit is greatest before 30<sup>+0</sup> weeks of gestation.<sup>25</sup>

Evidence level 1++

The neuroprotective effect of magnesium sulfate in women with PPROM has been demonstrated in a cohort study.<sup>27</sup>

Evidence level 2++

The RCOG<sup>28</sup> and NG25<sup>5</sup> recommend offering magnesium sulfate to women at risk of giving birth before 30<sup>+0</sup> weeks of gestation. NG25<sup>5</sup> recommends that magnesium sulfate should be considered when preterm birth is anticipated between 30<sup>+0</sup> and 33<sup>+6</sup> weeks.

Evidence level 4

### 6.4 Should tocolytic agents be used?

Recommendation	Evidence Level	Strength	Rationale for the recommendation
<b>Tocolysis in patients with PPROM is not recommended</b>	<b>1++</b>	<b>A</b>	A Cochrane review found that tocolysis does not significantly improve perinatal outcome and might be associated with an increased risk of chorioamnionitis

A Cochrane review found that, compared with placebo, tocolysis in PPROM is associated with an average 73 hours longer latency of delivery (95% CI 20–126) and fewer births within 48 hours (RR 0.55, 95% CI 0.32–0.95).<sup>29</sup> Tocolysis was associated with an increased risk of a 5-minute Apgar score of less than 7 and an increased need for ventilation support. For women before 34<sup>+0</sup> weeks of gestation, tocolysis increased the risk of chorioamnionitis. The review concluded that there is insufficient evidence to support the use of tocolysis in women with PPROM, as there is an increase in maternal chorioamnionitis without significant benefits to the neonate

Evidence level 1+

More recent publications have shown that compared with no tocolysis, tocolysis is not associated with improved neonatal outcomes.<sup>30,31</sup>

Evidence level I+

### 6.5 Can women be monitored at home?

Recommendation	Evidence Level	Strength	Rationale for the recommendation
<b>The decision to offer outpatient care to women with PPRM should be made on an individual basis, taking into account markers of delivery latency</b>	3	✓	Retrospective cohort studies found no differences in maternal or neonatal outcomes when planned home versus hospital care was compared
<b>The optimal method of monitoring to predict adverse fetal outcome after PPRM has not been determined</b>	2++	B	A Cochrane review found insufficient evidence to allow recommendations

A Cochrane review to assess the safety, cost and women's views about planned home versus hospital care for women with PPRM identified only two relatively small trials (116 women) so that meaningful differences between the groups could not be detected.<sup>32</sup> Retrospective cohort studies from Canada (173 women),<sup>33</sup> and France (414 women),<sup>34</sup> found no difference in maternal morbidity, or neonatal morbidity or mortality between the groups

Evidence level 3

If delivery seems imminent, then in-patient care is indicated to prepare the woman for birth (including, if relevant, the administration of intravenous magnesium sulphate).

The decision to offer outpatient care to women with PPRM, following a period of in-patient care, should be made on an individual basis. Factors including past obstetric history, support at home and distance from the hospital should be taken into account in discussion with the woman about her preferences, and markers of delivery latency should be assessed (the presence of antepartum haemorrhage, amniotic fluid volume, gestational age at which PPRM occurs and clinical and laboratory markers of infection).<sup>34,35</sup> When considering the gestational age at which PPRM occurs, delivery latency remains relatively constant from 24<sup>+0</sup> to 28<sup>+0</sup> weeks' gestation at 8–10 days (median) and then decreases to 5 days (median) at 31<sup>+0</sup> weeks.<sup>3</sup>

Evidence level 3

A case-control study has shown that women with clinically diagnosed PPRM who have reduced amniotic fluid volumes on ultrasound are more likely to give birth within 7 days from membrane rupture.<sup>36</sup>

Evidence level 2+

A retrospective cohort study of women with PPRM who had planned home care, found that membrane rupture occurring before 26<sup>+0</sup> weeks', non-cephalic presentation and oligohydramnios were associated with an increased risk of 'complication' (defined as fetal death, placental abruption, umbilical cord prolapse, delivery outside of hospital and neonatal death). The authors concluded that hospital based care should be recommended to women who have all three of these features.<sup>37</sup>

Evidence level 2–

A survey of fetal medicine specialists in the United States found substantial variations in fetal monitoring following PPRM.<sup>38</sup> In the UK, most clinicians would monitor fetal growth on ultrasound scan fortnightly, and assess amniotic fluid and umbilical artery Doppler studies weekly, although a Cochrane review on

Evidence level I++

methods to monitor the fetus following PPROM found insufficient evidence (three randomised controlled trials) to allow recommendations to be made.<sup>39</sup>

### 6.6 *Is there a role for amnioinfusion in PPROM?*

Recommendation	Evidence Level	Strength	Rationale for the recommendation
<b>In PPROM, amnioinfusion is not recommended as part of routine clinical practice</b>	<b>1+</b>	<b>B</b>	Cochrane review found some benefits of amnioinfusion, but questioned the quality of the evidence

Amnioinfusion might improve neonatal outcomes in PPROM by preventing umbilical cord compression, postural deformities, pulmonary hypoplasia and intrauterine infection.<sup>40</sup> A Cochrane systematic review of five trials (using the data from four) found that amnioinfusion is associated with: improved fetal umbilical artery pH at delivery, reduced variable decelerations in labour, neonatal death, neonatal sepsis, pulmonary hypoplasia and puerperal sepsis.<sup>40</sup> Since the positive findings were due to one trial with unclear allocation concealment, the review authors conclude that further evidence is required before amnioinfusion for PPROM can be recommended for routine clinical practice

Evidence level 1+

A further Cochrane review investigating amnioinfusion in PPROM occurring before 26 weeks of gestation found no eligible trials.<sup>41</sup>

### 6.7 *Should women with PPROM be offered emotional support?*

Recommendation	Evidence Level	Strength	Rationale for the recommendation
<b>Women with PPROM and their partners should be offered additional emotional support during pregnancy and postnatally.</b>	<b>4</b>	<b>↘</b>	Cohort studies have shown that posttraumatic stress disorder occurs in a substantial number of women whose pregnancy is complicated by PPROM.

Prospective cohort studies have shown that posttraumatic stress disorder is more common in women whose pregnancies were complicated by PPROM compared to uncomplicated controls (14% versus 2% antenatally, and 17% versus 3% at 6 weeks postnatal).<sup>42</sup>

Evidence level 2+

Women with PPROM and their partners should be offered access to additional emotional support, both during pregnancy and postnatally.

## 7. Birth

### 7.1 *When is the appropriate time to deliver the baby?*

Recommendation	Evidence Level	Strength	Rationale for the recommendation
Women whose pregnancy is complicated by PPRM after 24 <sup>+0</sup> weeks' gestation and who have no contraindications to continuing the pregnancy should be offered expectant management until 37 <sup>+0</sup> weeks; timing of birth should be discussed with each woman on an individual basis with careful consideration of patient preference and ongoing clinical assessment	1++	A	A Cochrane review found benefits from expectant management, rather than early delivery, following PPRM in women with otherwise uncomplicated pregnancies.
The care of women with PPRM who are known to be colonised with group B streptococcus, is addressed in Green-top Guideline No. 36	4	D	See RCOG Green-top Guideline No. 36. <sup>6</sup>

The previous edition of this Green-top Guideline recommended that delivery of the baby should be considered at 34<sup>+0</sup> weeks' gestation. More recently, a Cochrane review of 3617 women explored the effect of planned early delivery versus expectant management for women with PPRM.<sup>43</sup> The authors conclude that in women with PPRM 'with no contraindications to continuing the pregnancy, expectant management with careful monitoring is associated with better outcomes for the mother and baby'. The Cochrane review found no differences between early birth and expectant management in neonatal sepsis or infection. Early delivery increased the incidence of respiratory distress syndrome (RR 1.26, 95% CI 1.05–1.53), and an increased rate of caesarean section (RR 1.26, 95% CI 1.11–1.44). There were no differences in overall perinatal mortality or intrauterine deaths when comparing early delivery with expectant management. Early birth was associated with a higher rate of neonatal death (RR 2.55, 95% CI 1.17–5.56) and need for ventilation (RR 1.27, 95% CI 1.02–1.58).<sup>43</sup>

Evidence level 1++

The results and conclusions of the Cochrane review are influenced by those trials assessing 'late' PPRM (34<sup>+0</sup> to 36<sup>+6</sup> weeks' gestation) such as the PPROMPT trial<sup>2</sup> and it is less clear whether expectant management to 37<sup>+0</sup> weeks' gestation is appropriate for women who experience PPRM at earlier gestations. The Cochrane review acknowledges that research is required to determine which groups of women with PPRM would not benefit from expectant management, including gestational age at presentation.

The individual studies included in the Cochrane review<sup>43</sup> had a number of 'exclusion criteria' including: active labour, chorioamnionitis, concerns about fetal wellbeing, monochorionic multiple pregnancy, hypertensive disorders and other contraindications to continuing the pregnancy. Therefore the timing of birth should be discussed with each woman on an individual basis with careful consideration of patient preference and ongoing clinical assessment.

RCOG Green-top Guideline No. 36<sup>6</sup> addresses the management of PPRM in women known to be colonized with group B streptococcus

Evidence level 4

## 8. Care in a subsequent pregnancy following PPRM

### 8.1 Who should care for woman in a subsequent pregnancy?

Recommendation	Evidence Quality	Strength	Rationale for the recommendation
In a subsequent pregnancy following PPRM, women should be cared for by an obstetrician with an interest in preterm birth	4	✓	The risk of PPRM in subsequent pregnancies is increased

A population based cohort study found that pregnancies complicated by PPRM are at increased risk of recurrent PPRM in subsequent pregnancies (OR 8.7, 95% CI 6.7–11.4 in white women and OR 7.2, 95% CI 5.1–10.1 in African American women).<sup>44</sup> This study also found that a short inter-pregnancy interval is associated with greater risk

Evidence level 2+

In pregnancies following PPRM, women should be cared for by an obstetrician with an interest in preterm birth; ideally this would be in a dedicated preterm labour clinic. Modifiable risk factors, such as smoking<sup>45</sup> and respiratory diseases<sup>46</sup> should be addressed. There is evidence that screening for lower genital tract infections and midwife continuity throughout antenatal care are beneficial in preventing preterm birth.<sup>47</sup> Clinicians may offer these women genital tract screening for infection and/or serial transvaginal ultrasound scans to determine the cervical length, but the evidence to support these interventions is lacking.<sup>5</sup>

## 9. Recommendations for future research

- Studies are required to determine the antibiotic of choice and duration of treatment following PPRM.
- Controlled trials are required to determine whether magnesium sulphate has a role in PPRM when delivery is anticipated between 30<sup>+0</sup> and 33<sup>+6</sup> weeks of gestation.
- Studies comparing a single bolus of magnesium sulphate with a longer intravenous infusion are required.
- Methods to monitor the fetus following PPRM require further investigation.
- The role of sealants to 'repair' fetal membranes is currently under investigation.
- Studies are required to determine whether there is a role for amnioinfusion in PPRM.
- Trials are needed to determine which groups of women with PPRM would not benefit from expectant management.

## 10. Auditable topics

- Proportion of women with PPRM who are offered antibiotics for 10 days following PPRM, or until the woman is in established labour (100%).
- Proportion of women who experience PPRM between 24<sup>+0</sup> and 33<sup>+6</sup> weeks of gestation who are offered corticosteroids (100%).
- Proportion of women less than 30<sup>+0</sup> weeks' gestation who receive magnesium sulphate within 24 hours prior to birth (100%).
- Proportion of women with PPRM who are given the opportunity to discuss their care with a neonatologist (100%).
- Proportion of women with PPRM who birth in a centre without adequate facilities to care for their baby (0%)

## 11. Useful links and support groups

- Royal College of Obstetricians and Gynaecologists. *When your waters break early*. Information for you. London: RCOG; 2019.
- Little Heartbeats, a support group that promotes the awareness of PPRM [[www.little-heartbeats.org.uk](http://www.little-heartbeats.org.uk)].

### *Acknowledgments*

The RCOG would like to thank Dr Sarah Prince for her assistance in developing the new Green-top Guideline format.

### *Disclosure of interest*

AJT has declared no conflicts of interest. Full disclosure of interests for the developer, Guidelines Committee and peer reviewers are available to view online as supporting information.

### *Funding*

All those involved in the development of the Green-top Guidelines, including the Guidelines Committee, Guidelines Committee co-chairs, guideline developers, peer reviewers and other reviewers, are unpaid volunteers and receive no direct funding for their work in producing the guideline. The only exception to this are the Guidelines Committee members who receive reimbursement for expenses for attending Guidelines Committee meetings for standard RCOG activities; this is standard as per RCOG rules.

## Supporting Information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Infographic S1. Infographic version of the guideline

Audio S1. Audio version of the guideline

Appendix S1. PPRM literature search strategy

Appendix S2. PPRM search strategy top up

## References

1. Mercer BM. Preterm premature rupture of the membranes. *Obstet Gynecol* 2003;101:178–93.
2. Morris JM, Roberts CL, Bowen JPJ, Bond DM, Algert CS, Thornton JG, Crowther CA. Immediate delivery compared with expectant management after preterm pre-labour rupture of the membranes close to term (PPROMT trial): a randomised controlled trial. *Lancet* 2016;387:444–52.
3. Peaceman AM, Lai Y, Rouse DJ, Spong CY, Mercer BM, Varner MW, et al. Length of latency with preterm premature rupture of membranes before 32 weeks' gestation. *Am J Perinatol* 2015;32:57–62.
4. Dale PO, Tanbo T, Bendvold E, Moe N. Duration of the latency period in preterm premature rupture of the membranes. Maternal and neonatal consequences of expectant management. *Eur J Obstet Gynecol Reprod Biol* 1989;30:257–62.
5. National Institute for Health and Care Excellence. *Preterm Labour and Birth*. NICE guideline 25. London: NICE; 2015.
6. Hughes RG, Brocklehurst P, Steer PJ, Heath P, Stenson BM on behalf of the Royal College of Obstetricians and Gynaecologists. Prevention of early-onset neonatal group B streptococcal disease. Green-top Guideline No. 36. *BJOG* 2017;124:e280–e305.
7. Royal College of Obstetricians and Gynaecologists. *Development of RCOG Green-top Guidelines*. Clinical Governance Advice No. 1. London: RCOG; 2015.
8. Palacio M, Kühnert M, Berger R, Larios CL, Marcellin L. Meta-analysis of studies on biochemical marker tests for the diagnosis of premature rupture of membranes: comparison of performance indexes. *BMC Pregnancy Childbirth* 2014;14:183.

9. Igbinosi I, Moore FA 3rd, Johnson C, Block JE. Comparison of rapid immunoassays for rupture of fetal membranes. *BMC Pregnancy Childbirth* 2017;17:128.
10. Jayaprakash TP, Wagner EC, van Schalkwyk J, Albert AYK, Hill JE, Money DM, PPRM Study Group. High diversity and variability in the vaginal microbiome in women following preterm premature rupture of membranes (PPROM): a prospective cohort study. *PLoS ONE* 2016;11:e0166794.
11. Danesh A, Janghorbani M, Khalatbari S. Effects of antenatal corticosteroids on maternal serum indicators of infection in women at risk for preterm delivery: a randomized trial comparing betamethasone and dexamethasone. *J Res Med Sci* 2012;17:911.
12. Caloone J, Rabilloud M, Boutitie F, Traverse-Glehen A, Allias-Montmayeur F, Denis L, et al. Accuracy of several maternal seric markers for predicting histological chorioamnionitis after preterm premature rupture of membranes: a prospective and multicentric study. *Eur J Obstet Gynecol Reprod Med* 2016;205:133–40.
13. Sabogal CP, Fonseca J, Garcia-Perdomo HA. Validation of diagnostic tests for histologic chorioamnionitis: systematic review and meta-analysis. *Eur J Obstet Gynecol Reprod Biol* 2018;228:13–26.
14. Knight M, Nair M, Tuffnell D, Kenyon S, Shakespeare J, Brocklehurst P, et al. *Saving Lives, Improving Mothers' Care - Surveillance of Maternal Deaths in the UK 2012-14 and Lessons Learned to Inform Maternity Care from the UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity 2009-14*. Oxford: National Perinatal Epidemiology Unit, University of Oxford; 2016.
15. Kenyon S, Boulvain M, Neilson JP. Antibiotics for preterm rupture of membranes. *Cochrane Database Syst Rev* 2013;:CD001058.
16. Kenyon S, Pike K, Jones DR, Brocklehurst P, Marlow N, Salt A, et al. Childhood outcomes after prescription of antibiotics to pregnant women with preterm rupture of the membranes: 7-year follow-up of the ORACLE I trial. *Lancet* 2008;372:1310–8.
17. Lee JH, Romero R, Kim SM, Chaemsaitong P, Park CW, Park JS, et al. A new anti-microbial combination prolongs the latency period, reduces acute histologic chorioamnionitis as well as funisitis, and improves neonatal outcomes in preterm PROM. *J Matern Fetal Neonatal Med* 2016;29:707–20.
18. Chang KH, Kim HJ, Yu HJ, Lee J, Kim JS, Choi SJ, et al. Comparison of antibiotic regimens in preterm premature rupture of membranes: neonatal morbidity and 2-year follow-up of neurologic outcome. *J Matern Fetal Neonatal Med* 2017;30:2212–8.
19. Kenyon SL, Taylor DJ, Tarnow-Mordi W, for the ORACLE Collaborative Group. Broad spectrum antibiotics for preterm, prelabour rupture of fetal membranes: the ORACLE I randomized trial. *Lancet* 2001;357:979–88.
20. Magann EF, Haram K, Ounpraseuth S, Mortensen JH, Spencer HJ, Morrison JC. Use of corticosteroids in special circumstances: a comprehensive review. *Acta Obstet Gynecol Scand* 2017;96:395–409.
21. Been JV, Degraeuwe PL, Kramer BW, Zimmermann LJ. Antenatal steroids and neonatal outcome after chorioamnionitis: a meta-analysis. *BJOG* 2011;118:113–22.
22. Travers CP, Clark RH, Spitzer AR, Das A, Garite TJ, Carlo WA. Exposure to any antenatal corticosteroids and outcomes in preterm infants by gestational age: prospective cohort study. *BMJ* 2017;356:j1039.
23. Ehret DE, Edwards EM, Greenberg LT, Bernstein IM, Buzas JS, Soll RF, et al. Association of antenatal steroid exposure with survival among infants receiving postnatal life support at 22 to 25 weeks' gestation. *JAMA Network Open* 2018;1:e183235.
24. Doyle LW, Crowther CA, Middleton P, Marret S, Rouse D. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. *Cochrane Database Syst Rev* 2009;:CD004661.
25. Costantine MM, Weiner SJ, Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Effects of antenatal exposure to magnesium sulfate on neuroprotection and mortality in preterm infants: a meta-analysis. *Obstet Gynecol* 2009;114:354–64.
26. Conde-Agudelo A, Romero R. Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks of gestation: a systematic review and metaanalysis. *Am J Obstet Gynecol* 2009;200:595–609.
27. Jung EJ, Byun JM, Kim YN, Lee KB, Sung MS, Kim KT, et al. Antenatal magnesium sulfate for both tocolysis and fetal neuroprotection in premature rupture of the membranes before 32 weeks' gestation. *J Matern Fetal Neonatal Med* 2018;31:1431–41.
28. Royal College of Obstetricians and Gynaecologists. *Magnesium Sulphate to Prevent Cerebral Palsy following Preterm Birth*. Scientific Impact Paper No. 29. London: RCOG; 2011.
29. Mackeen AD, Seibel-Seamon J, Muhammad J, Baxter JK, Berghella V. Tocolytics for preterm premature rupture of membranes. *Cochrane Database Syst Rev* 2014;:CD007062.
30. Nijman TAJ, van Vliet EOG, Naaktgeboren CA, Oude RK, de LT, Bax CJ, et al. Nifedipine versus placebo in the treatment of preterm prelabour rupture of membranes: a randomised controlled trial. Assessment of perinatal outcome by use of tocolysis in early labor – APOSTEL IV trial. *Eur J Obstet Gynecol Reprod Med* 2016;205:79–84.
31. Lorthe E, Goffinet F, Marret S, Vayssiere C, Flamant C, Quere M, et al. Tocolysis after preterm premature rupture of membranes and neonatal outcome: a propensity-score analysis. *Am J Obstet Gynecol* 2017;217:212.
32. Abou El Senoun G, Dowswell T, Mousa HA. Planned home versus hospital care for preterm prelabour rupture of the membranes (PPROM) prior to 37 weeks' gestation. *Cochrane Database Syst Rev* 2014;:CD008053.
33. Palmer L, Grabowska K, Burrows J, Rowe H, Billing E, Metcalfe A. A retrospective cohort study of hospital versus home care for pregnant women with preterm prelabour rupture of membranes. *Int J Gynecol Obstet* 2017;137:180–4.
34. Dussaux C, Senat MV, Bouchghoul H, Benachi A, Mandelbrot L, Kayem G. Preterm premature rupture of membranes: is home care acceptable? *J Matern Fetal Neonatal Med* 2018;17:2284–92.
35. Phupong V, Kulmala L. Factors associated with latency period in preterm prelabour rupture of membranes. *J Matern Fetal Neonatal Med* 2016;29:2650–3.
36. Mehra S, Amon E, Hopkins S, Gavard JA, Shyken J. Transvaginal cervical length and amniotic fluid index: can it predict delivery latency following preterm premature rupture of membranes? *Am J Obstet Gynecol* 2015;212:400.
37. Petit C, Deruelle P, Behal H, Rakza T, Balagny S, Subtil D, et al. Preterm premature rupture of membranes: which criteria contradict home care management? *Acta Obstet Gynecol Scand* 2018;97:1499–507.
38. Ramsey PS, Nuthalapaty FS, Lu G, Ramin S, Nuthalapaty ES, Ramin KD. Contemporary management of preterm premature rupture of membranes (PPROM): a survey of maternal-fetal medicine providers. *Am J Obstet Gynecol* 2004;191:1497–502.
39. Sharp GC, Stock SJ, Norman JE. Fetal assessment methods for improving neonatal and maternal outcomes in preterm prelabour rupture of membranes. *Cochrane Database Syst Rev* 2014;:CD010209.
40. Hofmeyr GJ, Eke AC, Lawrie TA. Amnioinfusion for third trimester preterm premature rupture of membranes. *Cochrane Database Syst Rev* 2014;:CD000942.

- 
41. Van Teeffelen S, Pajkrt E, Willekes C, Van Kuijk SM, Mol BW. Transabdominal amnioinfusion for improving fetal outcomes after oligohydramnios secondary to preterm prelabour rupture of membranes before 26 weeks. *Cochrane Database Syst Rev* 2013; CD009952.
  42. Stamrood CAI, Wesses I, Doornbos B, Aarnoudse JG, van den Berg PP, Schultz W, et al. Posttraumatic stress disorder following preeclampsia and PPROM: a prospective study with 15 months follow-up. *Reprod Sci* 2011;18:645–53.
  43. Bond DM, Middleton P, Levett KM, van der Ham DP, Crowther CA, Buchanan SL, et al. Planned early birth versus expectant management for women with preterm prelabour rupture of membranes prior to 37 weeks' gestation for improving pregnancy outcome. *Cochrane Database of Syst Rev* 2017; CD004735.
  44. Getahun D, Strickland D, Ananth CV, Fassett MJ, Sacks DA, Kirby RS, et al. Recurrence of preterm premature rupture of membranes in relation to interval between pregnancies. *Am J Obstet Gynecol* 2010;202:570.e1–6.
  45. England MC, Benjamin A, Abenhaim HA. Increased risk of preterm premature rupture of membranes at early gestational ages among maternal cigarette smokers. *Am J Perinatol* 2013;30:821–6.
  46. Getahun D, Ananth CV, Oyelese Y, Peltier MR, Smulian JC, Vintzileos AM. Acute and chronic respiratory diseases in pregnancy: association with spontaneous premature rupture of membranes. *J Matern Fetal Neonatal Med* 2007;20:669–75.
  47. Medley N, Vogel JP, Care A, Alfirevic Z. Interventions during pregnancy to prevent preterm birth: an overview of Cochrane systematic reviews. *Cochrane Database of Syst Revs* 2018; CD012505.

This guideline was produced on behalf of the Royal College of Obstetricians and Gynaecologists by:

**Dr AJ Thomson MRCOG, Paisley.**

and peer reviewed by:

Professor AL David FRCOG, University College London, London; E Lorthe, RM, PhD, Paris; M Griffiths, Bedfordshire; MA Oudijk, Amsterdam UMC, the Netherlands; S Kenyon RM, MA, PhD, University of Birmingham, Birmingham; Miss S Jha MD, FRCOG, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield; A Pickersgill FRCOG, Manchester University NHS Foundation Trust, Manchester; L Thomas, RCOG, Epsom; Professor JE Norman, University of Edinburgh, Edinburgh; M Costantine, MD, The University of Texas Medical Branch, Houston, TX, USA; V Phupong FRCOG, Chulalongkorn University, Bangkok; Dr NA Khan, Al Qassmiya Women's and Child Hospital, Sharjah, United Arab Emirates; UK National Screening Committee Evidence Team; G Kumar FRCOG, Wrexham Maelor Hospital, Wrexham; D Fraser FRCOG, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich; S Roy MA MRCS MRCP, Cambridge University Hospitals NHSFT, Cambridge; Little Heartbeats; H Eadon, BPharm MSc MRPharmS, National Guideline Alliance, London; Harris Wellbeing Preterm Birth Centre; J Girling, Chelsea and Westminster Hospital NHS Foundation Trust, London; EF Magann FACOG, University of Arkansas for Medical Sciences, Little Rock, AR, USA; Birth Trauma Association; PS Yeh MRCOG, London North West University Healthcare NHS Trust, London; RCOG Women's Network; Professor DOC Anumba, MBBS FWACS FRCOG MD LL.M (Medical Law), The University of Sheffield, Sheffield; L Chappell, King's College London, London; H Mactier, Honorary Secretary of the British Association of Perinatal Medicine, Glasgow.

Committee lead reviewers were: Dr B Kumar FRCOG, Wrexham and Dr B Magowan FRCOG, Melrose

The chair of the Guidelines Committee were: Dr MA Ledingham FRCOG, Glasgow<sup>1</sup>; Dr B Magowan FRCOG, Melrose<sup>1</sup>; and Dr AM Thomson MRCOG, Paisley<sup>2</sup>.

<sup>1</sup>co-chairs from June 2018 <sup>2</sup>until May 2018

*All RCOG guidance developers are asked to declare any conflicts of interest. A statement summarising any conflicts of interest for this guideline is available from: <https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg73/>.*

The final version is the responsibility of the Guidelines Committee of the RCOG.

The guideline will be considered for update 3 years after publication, with an intermediate assessment of the need to update 2 years after publication.

#### DISCLAIMER

The Royal College of Obstetricians and Gynaecologists produces guidelines as an educational aid to good clinical practice. They present recognised methods and techniques of clinical practice, based on published evidence, for consideration by obstetricians and gynaecologists and other relevant health professionals. The ultimate judgement regarding a particular clinical procedure or treatment plan must be made by the doctor or other attendant in the light of clinical data presented by the patient and the diagnostic and treatment options available.

This means that RCOG Guidelines are unlike protocols or guidelines issued by employers, as they are not intended to be prescriptive directions defining a single course of management. Departure from the local prescriptive protocols or guidelines should be fully documented in the patient's case notes at the time the relevant decision is taken